Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up
Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up
复制标题
DOI：
10.1089/cap.2015.0031
复制
发表时间：
2016-05
影响因子：
1.9
通讯作者：
Suyi;Yangli;A. Steinmark;CaoQingjiu;WangYufeng
中科院分区：
文献类型：
--
作者：
Suyi;Yangli;A. Steinmark;CaoQingjiu;WangYufeng
摘要目的：本研究的目的是比较渗透释放口服系统哌甲酯（OROS MPH）或托莫西汀（ATX）治疗中国儿童和青少年注意缺陷多动障碍（ADHD）的短期疗效、耐受性和1年依从性。研究方法：符合精神疾病诊断和统计手册第4版（DSM-IV）ADHD标准的儿童和青少年被随机分配接受OROS MPH（n = 119）或ATX（n = 118）。参与者经历了1-4周的剂量滴定期以确定最佳剂量，然后维持该剂量4周（维持期）。在滴定期和维持期结束时每周进行一次疗效评估。主要疗效指标为ADHD评定量表-IV（ADHD-RS-IV）总分。缓解进一步分类为缓解（ADHD-RS-IV [18或9项]平均评分≤1）、稳健改善（ADHD-RS-IV ≥40%...
Abstract Objective: The purpose of this study was to compare the short-term efficacy, tolerability, and 1-year adherence in Chinese children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with either osmotic release oral system methylphenidate (OROS MPH) or atomoxetine (ATX). Methods: Children and adolescents meeting Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria for ADHD were randomly assigned to receive either OROS MPH (n = 119) or ATX (n = 118). Participants underwent a 1–4 week dose titration period to determine optimal dose, and then were maintained on that dose for 4 weeks (maintenance period). Assessment for efficacy was conducted every week over the titration period and at the end of the maintenance period. The primary efficacy measure was the investigator-rated total ADHD Rating Scale-IV (ADHD-RS-IV) score. Response was further classified as remission (ADHD-RS-IV [18 or 9 items] average score ≤1), robust improvement (ADHD-RS-IV ≥40% ...